Vericiguat Drug Asset Due Diligence Report 2026

This Vericiguat Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Vericiguat can convert its Small molecule drug profile and sGC biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Vericiguat (query alias: vericiguat)
Modality / target	Small molecule drug; sGC; sGC stimulants
Highest global status	Approved
Originator	Bayer AG
Active developers	Bayer AG, Merck Sharp & Dohme Corp., MSD R&D (China) Co. Ltd.

The MCP disease footprint includes Reduced ejection fraction co-occurrent and due to chronic heart failure, Chronic heart failure, Heart Failure. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07697833	Phase 4	Not yet recruiting	500	Quality of life using Kansas City Cardiomyopathy Questionnaire (KCCQ-12)
NCT07668739	Phase 4	Not yet recruiting	100	NTproBNP
NCT07697365	Not Applicable	Completed	40	Change in peak oxygen consumption (peak VO2) assessed by cardiopulmonary exercise testing

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

The Effect of Vericiguat on Endothelial Function in Patients with Heart Failure with Reduced Ejection Fraction: A Pilot Randomized Study

Phase 2; n=26; evaluation: Positive. Reported fields: FMD: Difference (%) = 0.7(95.0% CI, -1.1 to 2.5), P-Value = 0.4; FMD: Difference (%) = 0.7(95.0% CI, -1.1 to 2.5), P-Value = 0.4

Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction

Phase 2; n=45; evaluation: not stated. Reported fields: Absolute Change in Coronary Cross-sectional Area (in mm²) Within the Vericiguat Group as Assessed by Magnetic Resonance Imaging (MRI)(Mean): P-Value = 0.0005; Absolute Change in Coronary Cross-sectional Area (in mm²) Within the Vericiguat Group as Assessed by Magnetic Resonance Imaging (MRI)(Mean): P-Value = 0.0005; Absolute Change in Coronary Cross-sectional Area (in mm²) Within the Vericiguat Group as Assessed by Magnetic Resonance Imaging (MRI)(Mean) = -1.11 mm^2 (Standard Deviation, 1.17)

A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction

Phase 3; n=6106; evaluation: not stated. Reported fields: Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization: Participants With an Event Per 100 Patient-Years = 12.2 Pts. with event/100 patient-yrs at risk ; Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization: Participants With an Event Per 100 Patient-Years = 11.3 Pts. with event/100 patient-yrs at risk ; Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization: Participants With an Event Per 100 Patient-Years: Hazard Ratio (HR) = 0.93(95% CI, 0.83 - 1.04), P-Value = 0.219

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Vericiguat addresses Reduced ejection fraction co-occurrent and due to chronic heart failure, Chronic heart failure, Heart Failure. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-10-01	CKD Pharm to exclusively sell Bayer’s chronic heart failure drug Verquvo	Approved	Financial terms not disclosed
2024-04-05	Bayer and Dr. Reddy’s sign a marketing and distribution agreement for second brand of Vericiguat™ in India	Approved	Financial terms not disclosed
2014-05-06	Merck pays $1B to buy into Bayer's cardio future	Approved	US$1,000.0M upfront; US$1,100.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Treatment of chronic heart failure with vericiguat”. The milestone feed surfaced a patent-application signal described as “2-(5-FLUORO-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-b]PYRIDIN-3-YL)-5-NITROSOPYRIMIDIN-4,6-DIAMINE OR A SALT THEREOF, METHOD FOR THE PREPARATION THEREOF, AND USE THEREOF IN THE SYNTHESIS OF VERICIGUAT”. The milestone feed surfaced a patent-application signal described as “Solid state forms of vericiguat and process for preparation thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO